Massive data dive to map Germany's eye health

NCT ID NCT07308639

Not yet recruiting Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

Summary

This study aims to understand how common three serious eye diseases are in Germany and how treatment patterns have changed. Researchers will analyze existing health records from 50,000 people collected between 2009 and 2024. The goal is to map the occurrence of these diseases and see how many patients received a common sight-saving medication.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD); DIABETIC MACULAR EDEMA (DME); RETINAL VEIN OCCLUSION (RVO) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Bayer Vital GmbH

    Leverkusen, 51373, Germany

Conditions

Explore the condition pages connected to this study.